KI
BMRN icon

Kapitalo Investimentos’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kapitalo Investimentos’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,312
Closed -$322K – 502
2023
Q1 		$322K Buy
3,312
+2,852
+620% +$296K 0.11% 74
2022
Q4 		$47.6K Buy
+460
New +$43.2K 0.04% 133

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Kapitalo Investimentos's BMRN Position: Q2 2023 in Review

Kapitalo Investimentos sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 3,312 shares — an estimated $322K sold.

Kapitalo Investimentos first reported a position in BMRN in Q4 2022 and held it in 2 quarters. The position peaked at $322K in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Kapitalo Investimentos reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Kapitalo Investimentos sold 3,312 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $322K.
  • Kapitalo Investimentos first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Kapitalo Investimentos's BioMarin Pharmaceuticals position peaked at $322K in Q1 2023.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Kapitalo Investimentos's 13F filing for Q2 2023, filed 29 Mar 2024.